# US 2011/0256057 A1 · Cyclic Azapeptides as Integrin Markers and Methods of Using

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0256057 A1
- Document ID: US20110256057A1
- Status: Published application
- Kind: A1
- Application number: 13/113,580
- Filed: 2011-05-23
- Published: 2011-10-20
- Earliest claimed: 2007-07-27
- Assignees: Siemens Medical Solutions USA, Inc.
- Inventors: Hartmuth C. Kolb; Kai Chen; Joseph C. Walsh; Dhanalakshmi Kasi; Vani P. Mocharla; Gang Chen; Qianwa Liang; Tieming Zhao
- Web page: https://patentgrep.com/patent/US20110256057A1

## CPC

- A61K 51/08: Peptides, e.g. proteins {, carriers being peptides, polyamino acids, proteins}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 51/082: {the peptide being a RGD-containing peptide}
- A61P 35/00: Antineoplastic agents
- C07K 5/021: {containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds}
- C07K 7/54: with at least one abnormal peptide link in the ring
- C07K 7/64: Cyclic peptides containing only normal peptide links
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present application is directed to radiolabeled cyclic polyazapeptides, pharmaceutical compositions comprising radiolabeled cyclic polyazapeptides, and methods of using the radiolabeled cyclic polyazapeptides. Such polyazapeptides can be used in imaging studies, such as Positron Emitting Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).

## Claims

### Claim 1

A method of monitoring the level of integrin receptor expression within a body of a patient, the method comprising:
(a) administering to the patient a radiolabeled cycloazapeptide; and
(b) employing a nuclear imaging technique selected from the group consisting of positron emission tomography (PET) and single photon emission computed tomography (SPECT) for monitoring or visualizing a distribution of the radiolabeled cycloazapeptide within the body or within a portion thereof;
wherein the radiolabeled cycloazapeptide is of the formula:
Cyclo-(R-G-D-L1-L2)
wherein L1 and L2 are each independently selected from the group consisting of an amino acid, amino acid derivative, aza-amino acid and an aza-amino acid derivative, provided that at least one of L1 and L2 is an aza-amino acid or an aza-amino acid derivative; or a pharmaceutically acceptable salt thereof, optionally in the form of a single stereoisomer or mixture of stereoisomers thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cycloazapeptide is of the formula Z:
wherein:
each Q1, Q2, Q3, Q4 and Q5 is independently —CH— or N, provided that at least one of Q1, Q2, Q3, Q4 and Q5 is N;
R1 is hydrogen or is selected from the group consisting of a side chain of a natural amino acid and a side chain of an unnatural amino acid;
R2 and R3 are each independently selected from the group consisting of —H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyloxy, C1-C6 alkoxyalkyl, aryl, aryl-(C1-C6 alkylene)-, 3- to 7-membered carbocycle, 3- to 7-membered heterocycle, hydroxy-C1-C6-alkyl and C1-C6-alkoxy-C1-C6-alkyl, wherein the alkyl, alkenyl, alkynyl, alkyloxy, alkoxyalkyl, aryl, carbocycle and heterocycle groups are each optionally substituted;
R7 is absent or is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, aryl-(C1-C6 alkylene)-, a 3- to 7-membered carbocycle, and a 3- to 7-membered heterocycle, wherein the alkyl, alkenyl, alkynyl, aryl-alkylene, carbocycle and heterocycle groups are each optionally substituted; wherein R2, R3 and R7 are not all H;
R8 is hydrogen or is selected from the group consisting of a side chain of a natural amino acid and a side chain of an unnatural amino acid;
X is a 5 or 6-membered heterocycle or a linker comprising a hydrophilic moiety selected from the group consisting of hydroxyl, carbonyl, amide (—C(O)NH—), sulfonamide, sulfonate, phosphate, polar amino acid moiety, PEG moiety, sugar mimetic and sugar moiety, or a combination thereof;
Y is a 5 or 6-membered heterocycle or a linker comprising a hydrophilic moiety selected from the group consisting of hydroxyl, carbonyl, sulfonamide, sulfonate, phosphate, polar amino acid moiety, PEG moiety, sugar mimetic and sugar moiety;
where at least one of X and Y is a 5 or 6-membered heterocycle; and
w is 1, 2, 3, 4 or 5;
or a pharmaceutically acceptable salt thereof, optionally in the form of a single stereoisomer or mixture of stereoisomers thereof.

### Claim 3 (depends on 2)

The method of claim 2, wherein any one of X, Y, R2, R3, and R7 comprises a radionuclide selected from the group consisting of positron or gamma emitters.

### Claim 4 (depends on 3)

The method of claim 3, wherein the radionuclide is selected from the group consisting of 11C, 13N, 15O, 18F, 61Cu, 62Cu, 64Cu, 67Cu, 68Ga, 124I, 125I, 131I, 99Tc, 75Br, 153Gd and 32P.

### Claim 5

A method for imaging of blood vessel growth in solid tumors based on expression of an integrin binder within the body of a patient, the method comprising:
(a) administering to the patient a radiolabeled cycloazapeptide;
(b) employing a nuclear imaging technique selected from the group consisting of positron emission tomography (PET) and single photon emission computed tomography (SPECT) for imaging a distribution of the radiolabeled cycloazapeptide within the body or within a portion thereof; and
(c) correlating the distribution of the radiolabeled cycloazapeptide to the growth of blood vessels in solid tumors,
wherein the radiolabeled cycloazapeptide is of the formula:
Cyclo-(R-G-D-L1-L2)
wherein L1 and L2 are each independently selected from the group consisting of an amino acid, amino acid derivative, aza-amino acid and an aza-amino acid derivative, provided that at least one of L1 and L2 is an aza-amino acid or an aza-amino acid derivative; or a pharmaceutically acceptable salt thereof, optionally in the form of a single stereoisomer or mixture of stereoisomers thereof.

### Claim 6 (depends on 5)

The method of claim 5, wherein the cycloazapeptide is of the formula Z:
wherein:
each Q1, Q2, Q3, Q4 and Q5 is independently —CH— or N, provided that at least one of Q1, Q2, Q3, Q4 and Q5 is N;
R1 is hydrogen or is selected from the group consisting of a side chain of a natural amino acid and a side chain of an unnatural amino acid;
R2 and R3 are each independently selected from the group consisting of —H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyloxy, C1-C6 alkoxyalkyl, aryl, aryl-(C1-C6 alkylene)-, 3- to 7-membered carbocycle, 3- to 7-membered heterocycle, hydroxy-C1-C6-alkyl and C1-C6-alkoxy-C1-C6-alkyl, wherein the alkyl, alkenyl, alkynyl, alkyloxy, alkoxyalkyl, aryl, carbocycle and heterocycle groups are each optionally substituted;
R7 is absent or is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, aryl-(C1-C6 alkylene)-, a 3- to 7-membered carbocycle, and a 3- to 7-membered heterocycle, wherein the alkyl, alkenyl, alkynyl, aryl-alkylene, carbocycle and heterocycle groups are each optionally substituted; wherein R2, R3 and R7 are not all H;
R8 is hydrogen or is selected from the group consisting of a side chain of a natural amino acid and a side chain of an unnatural amino acid;
X is a 5 or 6-membered heterocycle or a linker comprising a hydrophilic moiety selected from the group consisting of hydroxyl, carbonyl, amide (—C(O)NH—), sulfonamide, sulfonate, phosphate, polar amino acid moiety, PEG moiety, sugar mimetic and sugar moiety, or a combination thereof;
Y is a 5 or 6-membered heterocycle or a linker comprising a hydrophilic moiety selected from the group consisting of hydroxyl, carbonyl, sulfonamide, sulfonate, phosphate, polar amino acid moiety, PEG moiety, sugar mimetic and sugar moiety;
where at least one of X and Y is a 5 or 6-membered heterocycle; and
w is 1, 2, 3, 4 or 5;
or a pharmaceutically acceptable salt thereof, optionally in the form of a single stereoisomer or mixture of stereoisomers thereof.

### Claim 7 (depends on 6)

The method of claim 6, wherein any one of X, Y, R2, R3, and R7 comprises a radionuclide selected from the group consisting of positron or gamma emitters.

### Claim 8 (depends on 7)

The method of claim 7, wherein the radionuclide is selected from the group consisting of 11C, 13N, 15O, 18F, 61Cu, 62Cu, 64Cu, 67Cu, 68Ga, 124I, 125I, 131I, 99Tc, 75Br, 153Gd and 32P.

### Claim 9

A method for imaging of blood vessel growth in solid tumors based on expression of integrin αvβ3 within the body of a patient, the method comprising:
(a) administering to the patient a radiolabeled cycloazapeptide;
(b) employing a nuclear imaging technique selected from the group consisting of positron emission tomography (PET) and single photon emission computed tomography (SPECT) for imaging a distribution of the radiolabeled cycloazapeptide within the body or within a portion thereof; and
(c) correlating the distribution of the radiolabeled cycloazapeptide to the growth of blood vessels in solid tumors,
wherein the radiolabeled cycloazapeptide is of formula II:
wherein:
each R1 is hydrogen or is independently selected from the group consisting of a side chain of a natural amino acid and a side chain of an unnatural amino acid;
R2 and R3 are each independently selected from the group consisting of —H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyloxy, C1-C6 alkoxyalkyl, aryl, aryl-(C1-C6 alkylene)-, 3- to 7-membered carbocycle, 3- to 7-membered heterocycle, hydroxy-C1-C6-alkyl and C1-C6-alkoxy-C1-C6-alkyl, wherein the alkyl, alkenyl, alkynyl, alkyloxy, alkoxyalkyl, aryl, carbocycle and heterocycle, groups are each optionally substituted, wherein R2 and R3 are not both H; and either R2 or R3, or both R2 and R3 comprise a radionuclide selected from the group consisting of 11C, 13N, 15O, 18F, 75Br, 124I, 125I and 131I; and
W is
where p is an integer between 0 and 15;
v is 0, 1, 2, or 3;
m is 0, 1 or 2;
each R4 is independently selected from the group consisting of —H, C1-C6 alkyl, C2-C6 alkenyl, and C2-C6 alkynyl, wherein the alkyl, alkenyl and alkynyl groups are each optionally substituted;
R5 is selected from the group consisting of —H, C1-C6 alkyl, C2-C6 alkenyl and C2-C6 alkynyl, wherein the alkyl, alkenyl and alkynyl groups are each optionally substituted and wherein the configuration of the chiral center that is substituted with the R5 substituent may be R or S or mixtures thereof;
or a pharmaceutically acceptable salt thereof, optionally in the form of a single stereoisomer or mixture of stereoisomers thereof.

### Claim 10 (depends on 9)

The method of claim 9 wherein:
each R1 is benzyl;
R2 is H;
R3 is an optionally substituted C1-C6 alkyl comprising a radionuclide selected from the group consisting of 11C, 13N, 15O, 18F, 75Br, 124I, 125I and 131I;
and W is
where p is 0, 1, 2, 3, 4 or 5.

### Claim 11

A method of monitoring the level of integrin αvβ3 or visualizing integrin αvβ3 expression within a body of a patient, the method comprising:
(a) administering to the patient a radiolabeled cycloazapeptide; and
(b) employing a nuclear imaging technique selected from the group consisting of positron emission tomography (PET) and single photon emission computed tomography (SPECT) for monitoring or visualizing a distribution of the radiolabeled cycloazapeptide within the body or within a portion thereof,
wherein the radiolabeled cycloazapeptide is of formula II:
wherein:
each R1 is hydrogen or is independently selected from the group consisting of a side chain of a natural amino acid and a side chain of an unnatural amino acid;
R2 and R3 are each independently selected from the group consisting of —H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyloxy, C1-C6 alkoxyalkyl, aryl, aryl-(C1-C6 alkylene)-, 3- to 7-membered carbocycle, 3- to 7-membered heterocycle, hydroxy-C1-C6-alkyl and C1-C6-alkoxy-C1-C6-alkyl, wherein the alkyl, alkenyl, alkynyl, alkyloxy, alkoxyalkyl, aryl, carbocycle and heterocycle, groups are each optionally substituted, wherein R2 and R3 are not both H; and either R2 or R3, or both R2 and R3 comprise a radionuclide selected from the group consisting of 11C, 13N, 15O, 18F, 75Br, 124I, 125I and 131I; and
W is
where p is an integer between 0 and 15;
v is 0, 1, 2, or 3;
m is 0, 1 or 2;
each R4 is independently selected from the group consisting of —H, C1-C6 alkyl, C2-C6 alkenyl, and C2-C6 alkynyl, wherein the alkyl, alkenyl and alkynyl groups are each optionally substituted;
R5 is selected from the group consisting of —H, C1-C6 alkyl, C2-C6 alkenyl and C2-C6 alkynyl, wherein the alkyl, alkenyl and alkynyl groups are each optionally substituted and wherein the configuration of the chiral center that is substituted with the R5 substituent may be R or S or mixtures thereof;
or a pharmaceutically acceptable salt thereof, optionally in the form of a single stereoisomer or mixture of stereoisomers thereof.

### Claim 12 (depends on 11)

The method of claim 11 wherein:
each R1 is benzyl;
R2 is H;
R3 is an optionally substituted C1-C6 alkyl comprising a radionuclide selected from the group consisting of 11C, 13N, 15O, 18F, 75Br, 124I, 125I and 131I;
and W is
where p is 0, 1, 2, 3, 4 or 5.

### Claim 13

A method of monitoring the level of integrin αvβ3 or visualizing integrin αvβ3 expression within a body of a patient, the method comprising:
(a) administering to the patient a radiolabeled cycloazapeptide; and
(b) employing a nuclear imaging technique selected from the group consisting of positron emission tomography (PET) and single photon emission computed tomography (SPECT) for monitoring or visualizing a distribution of the radiolabeled cycloazapeptide within the body or within a portion thereof;
wherein the radiolabeled cycloazapeptide is of formula I:
wherein
R1 is hydrogen or is selected from the group consisting of a side chain of a natural amino acid and a side chain of an unnatural amino acid;
R2 and R3 are each independently selected from the group consisting of —H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyloxy, C1-C6 alkoxyalkyl, aryl, aryl-(C1-C6 alkylene)-, 3- to 7-membered carbocycle, 3- to 7-membered heterocycle, hydroxy-C1-C6-alkyl, and C1-C6-alkoxy-C1-C6-alkyl, wherein the alkyl, alkenyl, alkynyl, alkyloxy, alkoxyalkyl, aryl, carbocycle and heterocycle, groups are each optionally substituted;
R7 is absent or is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, aryl-(C1-C6 alkylene)-, a 3- to 7-membered carbocycle and a 3- to 7-membered heterocycle, wherein the alkyl, alkenyl, alkynyl, aryl-alkylene, carbocycle and heterocycle groups are each optionally substituted; wherein R2, R3 and R7 are not all H;
X is a 5 or 6-membered heterocycle or a linker comprising a hydrophilic moiety selected from the group consisting of hydroxyl, carbonyl, amide (—C(O)NH—), sulfonamide, sulfonate, phosphate, polar amino acid moiety, PEG moiety, sugar mimetic and sugar moiety, or a combination thereof;
Y is a 5 or 6-membered heterocycle, or a linker comprising a hydrophilic moiety selected from the group consisting of hydroxyl, carbonyl, sulfonamide, sulfonate, phosphate, polar amino acid moiety, PEG moiety, sugar mimetic and sugar moiety;
where at least one of X and Y is a 5 or 6-membered heterocycle; and
w is 1, 2, 3, 4 or 5;
wherein any one of X, Y, R2, R3, and R7 comprises a radionuclide selected from the group consisting of positron or gamma emitters.

### Claim 14 (depends on 13)

The method of claim 13, wherein the radiolabeled cycloazapeptide is selected from the group consisting of:
wherein
each R1 is hydrogen or is independently selected from the group consisting of a side chain of a natural amino acid and a side chain of an unnatural amino acid;
R2 and R3 are each independently selected from the group consisting of —H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyloxy, C1-C6 alkoxyalkyl, aryl, aryl-(C1-C6 alkylene)-, 3- to 7-membered carbocycle, 3- to 7-membered heterocycle, hydroxy-C1-C6-alkyl and C1-C6-alkoxy-C1-C6-alkyl, wherein the alkyl, alkenyl, alkynyl, alkyloxy, alkoxyalkyl, aryl, carbocycle and heterocycle, groups are each optionally substituted, wherein R2 and R3 are not both H; and either R2 or R3, or both R2 and R3 comprise a radionuclide selected from the group consisting of 11C, 13N, 15O, 18F, 61Cu, 62Cu, 64Cu, 67Cu, 68Ga, 124I, 125I, 131I, 99Tc, 75Br, 153Gd and 32P;
each of X and W is selected from the group consisting of:
where each R4 is independently selected from the group consisting of —H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyloxy, aryl, aryl-(C1-C6 alkylene)-, 3- to 7-membered carbocycle, 3- to 7-membered heterocycle, hydroxy-C1-C6-alkyl, C1-C6-alkoxy-C1-C6-alkyl and a PEG moiety, wherein the alkyl, alkenyl, alkynyl, alkoxy, aryl, carbocycle and heterocycle groups are each optionally substituted;
R5 is selected from the group consisting of —H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyloxy, aryl, aryl-(C1-C6 alkylene)-, 3- to 7-membered carbocycle, 3- to 7-membered heterocycle, hydroxy-C1-C6-alkyl, and C1-C6-alkoxy-C1-C6-alkyl, wherein the alkyl, alkenyl, alkynyl, alkyloxy, aryl, carbocycle and heterocycle, groups are each optionally substituted;
wherein the configuration of the chiral centers may be R or S or mixtures thereof;
v is 0, 1, 2, 3 or 4;
m is 0, 1, 2, 3 or 4; and
p is an integer between 1 and 25; and

### Claim 15 (depends on 13)

The method of claim 13, wherein any one of X, Y, R2, R3 and R7 further comprises a radionuclide selected from the group consisting of positron or gamma emitters.

### Claim 16 (depends on 13)

The method of claim 13, wherein Y is a 5 or 6-membered heterocycle; and X is a linker either comprising a sugar mimetic selected from the group consisting of a 4 to 6-membered carbocycle substituted with at least one hydroxyl group and a 5- to 6-membered heterocycle substituted with at least one hydroxyl group or comprising a sugar moiety selected from the group consisting of glucose and galactose.

### Claim 17 (depends on 15)

The method of claim 15 wherein:
Y is a 5 or 6-membered heterocycle;
X is selected from the group consisting of:
wherein Z is selected from the group consisting of:
W is selected from the group consisting of:
A is selected from the group consisting of:
each R1 is independently selected from the group consisting of a side chain of a natural amino acid and a side chain of an unnatural amino acid;
each R4 is independently selected from the group consisting of —H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyloxy, aryl, aryl-(C1-C6 alkylene)-, 3- to 7-membered carbocycle, 3- to 7-membered heterocycle, hydroxy-C1-C6-alkyl, C1-C6-alkoxy-C1-C6-alkyl and a PEG moiety, wherein the alkyl, alkenyl, alkynyl, alkoxy, aryl, carbocycle and heterocycle groups are each optionally substituted;
R5 is selected from the group consisting of —H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyloxy, aryl, aryl-(C1-C6 alkylene)-, 3- to 7-membered carbocycle, 3- to 7-membered heterocycle, hydroxy-C1-C6-alkyl and C1-C6-alkoxy-C1-C6-alkyl, wherein the alkyl, alkenyl, alkynyl, alkyloxy, aryl, carbocycle and heterocycle, groups are each optionally substituted;
each R6 is independently selected from the group consisting of —H, —OH, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyloxy, aryl-(C1-C6 alkylene)-, hydroxy-C1-C6-alkyl and C1-C6-alkoxy-C1-C6-alkyl, wherein the alkyl, alkenyl, alkynyl, alkyloxy and aryl-alkylene groups are each optionally substituted;
each v is 0, 1, 2, 3 or 4;
m is 0, 1, 2, 3 or 4;
p is an integer between 1 and 110;
q is 1, 2, 3 or 4;
r is 1, 2 or 3;
r′ is 0 or 1;
s is 1, 2, 3 or 4; and
the radionuclide is selected from the group consisting of 11C, 13N, 15O, 18F, 61Cu, 62Cu, 64Cu, 67Cu, 68Ga, 124I, 125I, 131I, 75Br, 153Gd and 32P;
wherein the configuration of the chiral centers may be R or S or mixtures thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein:
R1 is a side chain of a natural amino acid;
R7 is absent;
X is
Y is 1,2,3-triazolyl; and
R2 and R3 are each independently selected from the group consisting of —H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyloxy, C1-C6 alkoxyalkyl, aryl, aryl-(C1-C6 alkylene)-, 3- to 7-membered carbocycle, 3- to 7-membered heterocycle, hydroxy-C1-C6-alkyl and C1-C6-alkoxy-C1-C6-alkyl, wherein the alkyl, alkenyl, alkynyl, alkyloxy, alkoxyalkyl, aryl, carbocycle and heterocycle, groups are each optionally substituted, wherein R2 and R3 are not both H; and either R2 or R3, or both R2 and R3 comprise a radionuclide selected from the group consisting of 11C, 13N, 15O, 18F, 74Br, 124I, 125I and 131I.

### Claim 19

A method for imaging of blood vessel growth in solid tumors based on expression of integrin αvβ3 within the body of a patient, the method comprising:
(a) administering to the patient a radiolabeled cycloazapeptide;
(b) employing a nuclear imaging technique selected from the group consisting of positron emission tomography (PET) and single photon emission computed tomography (SPECT) for imaging a distribution of the radiolabeled cycloazapeptide within the body or within a portion thereof; and
c) correlating the distribution of the radiolabeled cycloazapeptide to the growth of blood vessels in solid tumors,
wherein the radiolabeled cycloazapeptide is selected from the group consisting of:
wherein:
R1 is hydrogen or is selected from the group consisting of a side chain of a natural amino acid and a side chain of an unnatural amino acid;
R2 and R3 are each independently selected from the group consisting of —H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyloxy, C1-C6 alkoxyalkyl, aryl, aryl-(C1-C6 alkylene)-, 3- to 7-membered carbocycle, 3- to 7-membered heterocycle, hydroxy-C1-C6-alkyl and C1-C6-alkoxy-C1-C6-alkyl, wherein the alkyl, alkenyl, alkynyl, alkyloxy, alkoxyalkyl, aryl, carbocycle and heterocycle, groups are each optionally substituted;
R7 is absent or is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, aryl-(C1-C6 alkylene)-, a 3- to 7-membered carbocycle, and a 3- to 7-membered heterocycle, wherein the alkyl, alkenyl, alkynyl, aryl-alkylene, carbocycle and heterocycle groups are each optionally substituted; wherein R2, R3 and R7 are not all H;
X is a 5 or 6-membered heterocycle or a linker comprising a hydrophilic moiety selected from the group consisting of hydroxyl, carbonyl, amide (—C(O)NH—), sulfonamide, sulfonate, phosphate, polar amino acid moiety, PEG moiety, sugar mimetic and sugar moiety, or a combination thereof;
Y is a 5 or 6-membered heterocycle or a linker comprising a hydrophilic moiety selected from the group consisting of hydroxyl, carbonyl, sulfonamide, sulfonate, phosphate, polar amino acid moiety, PEG moiety, sugar mimetic and sugar moiety;
where at least one of X and Y is a 5 or 6-membered heterocycle; and
w is 1, 2, 3, 4 or 5;
wherein any one of X, Y, R2, R3, and R7 comprises a radionuclide selected from the group consisting of positron or gamma emitters; and
wherein:
each R1 is hydrogen or is independently selected from the group consisting of a side chain of a natural amino acid and a side chain of an unnatural amino acid;
R2 and R3 are each independently selected from the group consisting of —H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyloxy, C1-C6 alkoxyalkyl, aryl, aryl-(C1-C6 alkylene)-, 3- to 7-membered carbocycle, 3- to 7-membered heterocycle, hydroxy-C1-C6-alkyl, and C1-C6-alkoxy-C1-C6-alkyl, wherein the alkyl, alkenyl, alkynyl, alkyloxy, alkoxyalkyl, aryl, carbocycle and heterocycle, groups are each optionally substituted, wherein R2 and R3 are not both H; and either R2 or R3, or both R2 and R3 comprise a radionuclide selected from the group consisting of 11C, 13N, 15O, 18F, 61Cu, 62Cu, 64Cu, 67Cu, 68Ga, 124I, 125I, 131I, 99Tc, 75Br, 153Gd and 32P;
each of X and W is selected from the group consisting of:
where each R4 is independently selected from the group consisting of —H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyloxy, aryl, aryl-(C1-C6 alkylene)-, 3- to 7-membered carbocycle, 3- to 7-membered heterocycle, hydroxy-C1-C6-alkyl, C1-C6-alkoxy-C1-C6-alkyl, and a PEG moiety, wherein the alkyl, alkenyl, alkynyl, alkoxy, aryl, carbocycle and heterocycle groups are each optionally substituted;
R5 is selected from the group consisting of —H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyloxy, aryl, aryl-(C1-C6 alkylene)-, 3- to 7-membered carbocycle, 3- to 7-membered heterocycle, hydroxy-C1-C6-alkyl and C1-C6-alkoxy-C1-C6-alkyl, wherein the alkyl, alkenyl, alkynyl, alkyloxy, aryl, carbocycle and heterocycle groups are each optionally substituted;
wherein the configuration of the chiral centers may be R or S or mixtures thereof;
v is 0, 1, 2, 3 or 4;
m is 0, 1, 2, 3 or 4; and
p is an integer between 1 and 25.

### Claim 20 (depends on 19)

The method of claim 19, wherein any one of X, Y, R2, R3 and R7 further comprises a radionuclide selected from the group consisting of positron or gamma emitters.

### Claim 21 (depends on 19)

The method of claim 19, wherein Y is a 5 or 6-membered heterocycle; and X is a linker either comprising a sugar mimetic selected from the group consisting of a 4 to 6-membered carbocycle substituted with at least one hydroxyl group and a 5- to 6-membered heterocycle substituted with at least one hydroxyl group or comprising a sugar moiety selected from the group consisting of glucose and galactose.

### Claim 22 (depends on 20)

The method of claim 20, wherein:
Y is a 5 or 6-membered heterocycle;
X is selected from the group consisting of:
wherein Z is selected from the group consisting of:
W is selected from the group consisting of:
A is selected from the group consisting of:
each R1 is independently selected from the group consisting of a side chain of a natural amino acid and a side chain of an unnatural amino acid;
each R4 is independently selected from the group consisting of —H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyloxy, aryl, aryl-(C1-C6 alkylene)-, 3- to 7-membered carbocycle, 3- to 7-membered heterocycle, hydroxy-C1-C6-alkyl, C1-C6-alkoxy-C1-C6-alkyl and a PEG moiety, wherein the alkyl, alkenyl, alkynyl, alkoxy, aryl, carbocycle and heterocycle groups are each optionally substituted;
R5 is selected from the group consisting of —H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyloxy, aryl, aryl-(C1-C6 alkylene)-, 3- to 7-membered carbocycle, 3- to 7-membered heterocycle, hydroxy-C1-C6-alkyl and C1-C6-alkoxy-C1-C6-alkyl, wherein the alkyl, alkenyl, alkynyl, alkyloxy, aryl, carbocycle and heterocycle, groups are each optionally substituted;
each R6 is independently selected from the group consisting of —H, —OH, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyloxy, aryl-(C1-C6 alkylene)-, hydroxy-C1-C6-alkyl and C1-C6-alkoxy-C1-C6-alkyl, wherein the alkyl, alkenyl, alkynyl, alkyloxy and aryl-alkylene groups are each optionally substituted;
each v is 0, 1, 2, 3 or 4;
m is 0, 1, 2, 3 or 4;
p is an integer between 1 and 110;
q is 1, 2, 3 or 4;
r is 1, 2 or 3;
r′ is 0 or 1;
s is 1, 2, 3 or 4; and
the radionuclide is selected from the group consisting of 11C, 13N, 15O, 18F, 61Cu, 62Cu, 64Cu, 67, 68Ga, 124I, 125I, 131I, 99Tc, 75Br, 153Gd and 32P;
wherein the configuration of the chiral centers may be R or S or mixtures thereof.

### Claim 23 (depends on 22)

The method of claim 22, wherein:
R1 is a side chain of a natural amino acid;
R7 is absent;
X is
Y is 1,2,3-triazolyl; and
R2 and R3 are each independently selected from the group consisting of —H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyloxy, C1-C6 alkoxyalkyl, aryl, aryl-(C1-C6 alkylene)-, 3- to 7-membered carbocycle, 3- to 7-membered heterocycle, hydroxy-C1-C6-alkyl and C1-C6-alkoxy-C1-C6-alkyl, wherein the alkyl, alkenyl, alkynyl, alkyloxy, alkoxyalkyl, aryl, carbocycle and heterocycle, groups are each optionally substituted, wherein R2 and R3 are not both H; and either R2 or R3, or both R2 and R3 comprise a radionuclide selected from the group consisting of 11C, 13N, 15O, 18F, 75Br, 124I, 125I and 131I.

### Claim 24

A method for imaging of blood vessel growth in solid tumors based on expression of integrin αvβ3 within the body of a patient, the method comprising:
(a) administering to the patient a radiolabeled cycloazapeptide;
(b) employing a nuclear imaging technique selected from the group consisting of positron emission tomography (PET) and single photon emission computed tomography (SPECT) for imaging a distribution of the radiolabeled cycloazapeptide within the body or within a portion thereof; and
(c) correlating the distribution of the radiolabeled cycloazapeptide to the growth of blood vessels in solid tumors,
wherein the radiolabeled cycloazapeptide is selected from the group consisting of:

### Claim 25

A method for selectively binding integrin receptors in a mammal, the method comprising administering a therapeutically effective amount of a cycloazapeptide of the formula Z:
wherein:
each Q1, Q2, Q3, Q4 and Q5 is independently —CH— or N, provided that at least one of Q1, Q2, Q3, Q4 and Q5 is N;
R1 is hydrogen or is selected from the group consisting of a side chain of a natural amino acid and a side chain of an unnatural amino acid;
R2 and R3 are each independently selected from the group consisting of —H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyloxy, C1-C6 alkoxyalkyl, aryl, aryl-(C1-C6 alkylene)-, 3- to 7-membered carbocycle, 3- to 7-membered heterocycle, hydroxy-C1-C6-alkyl and C1-C6-alkoxy-C1-C6-alkyl, wherein the alkyl, alkenyl, alkynyl, alkyloxy, alkoxyalkyl, aryl, carbocycle and heterocycle groups are each optionally substituted;
R7 is absent or is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, aryl-(C1-C6 alkylene)-, a 3- to 7-membered carbocycle, and a 3- to 7-membered heterocycle, wherein the alkyl, alkenyl, alkynyl, aryl-alkylene, carbocycle and heterocycle groups are each optionally substituted; wherein R2, R3 and R7 are not all H;
R8 is hydrogen or is selected from the group consisting of a side chain of a natural amino acid and a side chain of an unnatural amino acid;
X is a 5 or 6-membered heterocycle or a linker comprising a hydrophilic moiety selected from the group consisting of hydroxyl, carbonyl, amide (—C(O)NH—), sulfonamide, sulfonate, phosphate, polar amino acid moiety, PEG moiety, sugar mimetic and sugar moiety, or a combination thereof;
Y is a 5 or 6-membered heterocycle or a linker comprising a hydrophilic moiety selected from the group consisting of hydroxyl, carbonyl, sulfonamide, sulfonate, phosphate, polar amino acid moiety, PEG moiety, sugar mimetic and sugar moiety;
where at least one of X and Y is a 5 or 6-membered heterocycle; and
w is 1, 2, 3, 4 or 5;
or a pharmaceutical composition thereof.

### Claim 26 (depends on 25)

The method of claim 25, wherein the binding of integrin receptors is effective for reducing or eliminating tumor progression.

### Claim 27 (depends on 13)

The method of claim 13, further comprising:
(c) administering to the patient, a therapeutic agent;
(d) administering to the patient the radiolabeled cycloazapeptide; and
(e) employing the nuclear imaging technique for monitoring or visualizing a distribution of the radiolabeled cycloazapeptide within the body or within a portion thereof.

### Claim 28 (depends on 13)

The method of claim 13, further comprising:
(c) waiting for a period of time;
(d) administering to the patient the radiolabeled cycloazapeptide; and
(e) employing the nuclear imaging technique for monitoring or visualizing a distribution of the radiolabeled cycloazapeptide within the body or within a portion thereof.
